Non-alcoholic fatty liver disease historical perspective: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
'''Editor in Chief''': Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, [[User:C Michael Gibson |C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com] | '''Editor in Chief''': Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, [[User:C Michael Gibson |C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com] | ||
==Overview== | ==Overview== | ||
NAFLD/NASH was first described in a 1980 series of obese, non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of NAFLD has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref> The disease is most closely associated with the increasing obesity, insulin resistance, type two diabetes mellitus and | NAFLD/NASH was first described in a 1980 series of [[obese]], non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of [[NAFLD]] has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref> The disease is most closely associated with the increasing [[obesity]], [[insulin resistance]], [[type two diabetes mellitus]] and [[hyperlipidemia]] [[[endemic]] to the developed world. Roughly half of all patients with [[NAFLD]], however, do not meet criteria for [[metabolic syndrome]]. <ref>Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.</ref> | ||
==References== | ==References== | ||
Revision as of 20:09, 17 November 2012
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective |
|
FDA on Non-alcoholic fatty liver disease historical perspective |
|
CDC on Non-alcoholic fatty liver disease historical perspective |
|
Non-alcoholic fatty liver disease historical perspective in the news |
|
Blogs on Non-alcoholic fatty liver disease historical perspective |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
|
Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective |
Editor in Chief: Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, C. Michael Gibson, M.S., M.D. [1]
Overview
NAFLD/NASH was first described in a 1980 series of obese, non-alcoholic patients of the Mayo Clinic.[1] Since that seminal description, our understanding of NAFLD has progressed minimally. [2] The disease is most closely associated with the increasing obesity, insulin resistance, type two diabetes mellitus and hyperlipidemia [[[endemic]] to the developed world. Roughly half of all patients with NAFLD, however, do not meet criteria for metabolic syndrome. [3]
References
- ↑ Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
- ↑ Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.
- ↑ Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.